Microglial cell dysregulation in brain aging and neurodegeneration

The immune cells in your brain are supposed to protect you, and in a young brain, they do. They constantly survey the tissue, clear debris, and fight infection. However, aging breaks that contract in a specific way. The same cells that defend neurons begin to misfire, pumping out signals that slowly poison the very tissue they were built to defend. This reversal is the engine of this lecture. The cells in question are microglia, the brain's resident immune cells. Von Bernhardi and colleagues describe their normal role as constant surveillance of the brain parenchyma by scanning for damage, scavenging cellular waste, and participating in repair. In a healthy adult brain, microglia shift between a quiet baseline and an activated state depending on local signals. The system is responsive and, crucially, regulated. It activates when needed and turns off when the threat is gone. Aging systematically dismantles that regulation. Across normal aging, microglia acquire features compatible with chronic activation — not in response to any specific injury or infection, but as a remapping of baseline behavior. They begin expressing higher levels of inflammatory cytokines and mount exaggerated responses to pathological challenges. This is significant because aging is the single largest risk factor for neurodegenerative diseases, including Alzheimer's. Von Bernhardi and colleagues frame a working hypothesis: age-dependent changes in microglial regulation convert normally protective functions into chronic, damaging ones. Understanding the mechanism is the project. The clearest window into what changes is an experiment with lipopolysaccharide, or LPS — a bacterial endotoxin used to trigger an immune response. In young mice, LPS causes microglia to secrete predominantly nitric oxide. In aged mice, the identical stimulus produces a surge of reactive oxygen species, or ROS — unstable, oxygen-derived molecules that react with lipids, proteins, and nucleic acids, damaging whatever they contact. This isn't just more inflammation; it's a different kind of inflammation, and the distinction has consequences. Reactive oxygen species don't only damage biomolecules; they also act as signaling molecules. Von Bernhardi and colleagues highlight nuclear factor kappa B, or NF-kappa-B, as a redox-sensitive transcription factor that acts as the critical switch. Moderate levels of reactive oxygen species trigger a phosphorylation cascade that releases NF-kappa-B to enter the nucleus and drive the transcription of pro-inflammatory genes. In aged microglia, where reactive oxygen species production is sustained, NF-kappa-B remains active, feeding more inflammatory output, which generates more oxidative stress. It's a loop that doesn't close. That loop also generates interleukin-1 beta, a key inflammatory cytokine, through a two-part mechanism: mitochondria-derived reactive oxygen species and cathepsin B — a lysosomal protease released when lysosomal membranes are damaged — are both required for its production. The aged brain isn't just inflamed; it's caught in a self-reinforcing cycle between oxidative signaling and cytokine release. The cellular machinery behind this breakdown resides in two organelles: mitochondria and lysosomes. In aging microglia, mitochondrial DNA accumulates oxidative damage, which reduces the activity of electron transport complexes — especially complexes I and IV. Reduced complex I activity produces more reactive oxygen species, which damages more mitochondrial DNA. The cycle is vicious and self-sustaining. Autophagy, the cellular process that removes damaged mitochondria, normally limits this cycle. However, autophagy efficiency declines with age, so damaged mitochondria accumulate instead of getting cleared. Meanwhile, the lysosomal system, responsible for degrading cellular waste, loses capacity. When lysosomes are overwhelmed or damaged, cathepsin B leaks into the cytoplasm, which activates the NLRP3 inflammasome, a protein complex that drives the production and release of interleukin-1 beta and interleukin-18. The significance of this pathway is underscored by disease work: NLRP3 deficiency in an Alzheimer's mouse model reduced caspase-1 and interleukin-1 beta expression, improved amyloid-beta clearance, and restored spatial memory. Organelle-level failure translates directly into functional decline. What makes this picture particularly striking is what happens to the system that should stop it. Transforming growth factor beta 1, or TGF-beta-1, is a regulatory cytokine that normally reduces microglial inflammation. It limits LPS-induced activation, inhibits radical production, and promotes phagocytosis through a signaling pathway called Smad3. Here's the paradox: TGF-beta-1 is elevated in the aged brain. The brake signal is present, but the brake doesn't work. The problem lies with the receiver. Tichauer and colleagues, cited throughout von Bernhardi et al., demonstrated that the induction of the Smad3 pathway by inflammatory conditions is reduced in normal aging. The same impairment appears in Alzheimer's disease patients and mouse models, where it is linked to amyloid-beta accumulation and tangle formation. When Smad3 signaling is blunted, TGF-beta-1's canonical anti-inflammatory program fails to engage. The signal may instead divert into alternative branches — ERK, p38 MAPK, JNK — which can actually promote inflammation rather than suppress it. The functional consequence is concrete. Basal phagocytosis in one-year-old mice is slightly higher than in young mice, but that activity can no longer be increased by TGF-beta-1 or by inflammatory stimuli. Aged microglia have a higher baseline of debris uptake but have lost the ability to clear it effectively — they're uncoupled from proper lysosomal degradation. More baseline activity, less adaptive capacity, and less actual clearance. The brake exists, the signal is there, but the receptor is broken. Alzheimer's disease is where all of these failures converge. Microglial phagocytosis and degradation of amyloid-beta are reduced in aged cells. Genetic variants in TREM2, a key microglial regulator, are associated with substantially increased Alzheimer's risk. Acute increases in interleukin-1 beta and interleukin-6 can transiently reduce amyloid pathology, but chronic neuroinflammation fails to promote removal. Impaired phagocytosis, coupled with persistent inflammation, tips the balance decisively toward plaque accumulation. This inflammatory environment shapes tau pathology. Von Bernhardi and colleagues cite experiments where fibrillary amyloid-beta injected into aged rhesus cortex caused neurodegeneration, tau phosphorylation, and microglial proliferation — effects not seen in young animals. Deficits in antioxidant enzymes, such as superoxide dismutase, increase tau phosphorylation and enhance both amyloid and tau aggregation. The oxidative and proteostatic landscapes are interlinked. Nitric oxide adds another layer of damage through a process called S-nitrosylation — the abnormal modification of cysteine residues on proteins by nitric oxide, forming S-nitrosothiols that alter protein function. Von Bernhardi and colleagues document S-nitrosylation of mitochondrial complexes I and IV, of the GTPase Drp1, which governs mitochondrial dynamics and synaptic integrity, and of protein-disulfide isomerase, which protects against endoplasmic reticulum stress. Mitochondrial DNA oxidation in this context is reported to be ten times greater than nuclear DNA oxidation — a striking figure that explains why mitochondria are disproportionately affected. All of these modifications compound with each other, and they are amplified by crosstalk between microglia, astrocytes, and neurons. Impaired astrocytic glutamate transporters produce excitotoxic injury, while microglial recruitment to tau-bearing neurons drives further local inflammation. It is a self-perpetuating system. So, can any of it be slowed? Animal models provide mechanistic evidence that it can, though clinical proof remains ahead. Exercise, dietary restriction, and cognitive enrichment all reduce age-related microglial activation in aged animals. In APP and PS1 mice — a common Alzheimer's model — exercise improved neurobehavioral performance while reducing amyloid-beta levels and microglial activation. Part of that benefit is attributed to brain-derived neurotrophic factor, or BDNF, which has been shown to inhibit microglial activation. Dietary restriction reduces age-related microglial responses and shifts hypothalamic signaling toward an anti-inflammatory bias. Critically, both exercise and dietary restriction promote mitochondrial biogenesis and expression of mitochondrial transcription factor A, or TFAM, in rat brains. This links behavioral interventions directly to mitochondrial health and reduced oxidative stress. The mechanistic picture points toward a specific therapeutic target: restoration of TGF-beta-1 and Smad3 signaling. Because Smad3 induction is impaired in both normal aging and Alzheimer's models, restoring that pathway could re-engage the protective program that aged microglia have lost — inducible phagocytosis, suppressed cytokine release, and adaptive clearance. The research by von Bernhardi and colleagues identifies something more useful than the general fact that the brain ages. It identifies a failure mode — a set of interconnected breakdowns in mitochondria, lysosomes, and regulatory signaling — that explains why the brain's own immune cells stop protecting it. That's a very different perspective. Vague decline is hard to address, but a broken brake with a known mechanism is something you could, in principle, fix. This lecture was created by ennepō. Go to https://ennepo.ai to Discover, Create and Follow the latest research in your field. Read when you can. Listen when you want to.